Frances A. Collichio

Oncology

101 Manning Dr
Chapel Hill, NC 27514

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

ASO Visual Abstract: Implementing Paradigm-Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients.

ASO Visual Abstract: Implementing Paradigm-Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients.

Journal: Annals of surgical oncology

Published: July 03, 2026

Implementing Paradigm Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients.

Implementing Paradigm Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients.

Journal: Annals of surgical oncology

Published: March 11, 2026

Prognostic Value of a Novel Nuclear Grading of Cutaneous Melanoma: The UNC Chapel Hill Method.

Prognostic Value of a Novel Nuclear Grading of Cutaneous Melanoma: The UNC Chapel Hill Method.

Journal: The American journal of surgical pathology

Published: January 13, 2026

Symptomatic radiation necrosis after concurrent targeted therapy and stereotactic radiosurgery for brain metastases: a bicentric retrospective analysis.

Symptomatic radiation necrosis after concurrent targeted therapy and stereotactic radiosurgery for brain metastases: a bicentric retrospective analysis.

Journal: Journal of neuro-oncology

Published: December 04, 2025

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

Journal: Cancer discovery

Published: October 07, 2025

Anatomic Location Predicts Response Rates: Real World Outcomes With Over 1100 Cycles of Talimogene Laherparepvec Description: A Retrospective Review of a Prospectively Maintained Database.

Anatomic Location Predicts Response Rates: Real World Outcomes With Over 1100 Cycles of Talimogene Laherparepvec Description: A Retrospective Review of a Prospectively Maintained Database.

Journal: Annals of surgery

Published: April 29, 2025

Lymphangitic Melanomatosis: Case Report of Intralymphatic Spread of Melanoma in a 66-year-old Man.

Lymphangitic Melanomatosis: Case Report of Intralymphatic Spread of Melanoma in a 66-year-old Man.

Journal: The American Journal of dermatopathology

Published: April 04, 2024

Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy.

Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: June 12, 2023

Subspecialty Milestones and F-CCC: A New Tool to Assess Faculty.

Subspecialty Milestones and F-CCC: A New Tool to Assess Faculty.

Journal: The American journal of medicine

Published: May 03, 2023

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma.

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma.

Journal: Oncoimmunology

Published: May 01, 2023

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2023

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.

Journal: Nature medicine

Published: February 23, 2023

Showing 1-12 of 62

Last Updated: 09/26/2026